Trial Profile
A Randomised, Double-blind, Placebo-controlled, Event Driven, Phase III Study of Rosuvastatin 20 mg Once Daily in the Long Term Prevention of Recurrent Venous Thromboembolism in Patients With Deep Vein Thrombosis or Pulmonary Embolism.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2012
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Acronyms Du Lac
- Sponsors AstraZeneca
- 09 Dec 2010 Planned end date changed from 1 Oct 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned initiation date changed from 1 Sep 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 24 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.